Fabrication of deferasirox-decorated aptamer-targeted superparamagnetic iron oxide nanoparticles (SPION) as a therapeutic and magnetic resonance imaging agent in cancer therapy.

Publisher: Springer Country of Publication: Germany NLM ID: 9616326 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1327 (Electronic) Linking ISSN: 09498257 NLM ISO Abbreviation: J Biol Inorg Chem Subsets: MEDLINE

Original Publication: Berlin : Springer, c1996-

Antineoplastic Agents/*therapeutic use ; Contrast Media/*therapeutic use ; Deferasirox/*therapeutic use ; Iron Chelating Agents/*therapeutic use ; Magnetite Nanoparticles/*therapeutic use ; Neoplasms/*drug therapy; Animals ; Antineoplastic Agents/chemical synthesis ; Aptamers, Nucleotide/chemistry ; CHO Cells ; Cell Line, Tumor ; Contrast Media/chemical synthesis ; Cricetulus ; Deferasirox/chemistry ; Female ; Humans ; Immobilized Nucleic Acids/chemistry ; Immobilized Nucleic Acids/therapeutic use ; Iron Chelating Agents/chemical synthesis ; Kaplan-Meier Estimate ; Magnetic Resonance Imaging ; Magnetite Nanoparticles/chemistry ; Mice, Inbred BALB C ; Precision Medicine ; Propylamines/chemistry ; Silanes/chemistry ; Mice

In the current study, the synthesis of a theranostic platform composed of superparamagnetic iron oxide nanoparticles (SPION)-deferasirox conjugates targeted with AS1411 DNA aptamer was reported. In this regard, SPION was amine-functionalized by (3-aminopropyl)trimethoxysilane (ATPMS), and then deferasirox was covalently conjugated onto its surface. Finally, to provide guided drug delivery to cancerous tissue, AS1411 aptamer was conjugated to the complex of SPION-deferasirox. The cellular toxicity assay on CHO, C-26 and AGS cell lines verified higher cellular toxicity of targeted complex in comparison with non-targeted one. The evaluation of in vivo tumor growth inhibitory effect in C26 tumor-bearing mice illustrated that the aptamer-targeted complex significantly enhanced the therapeutic outcome in comparison with both non-targeted complex and free drug. The diagnostic capability of the prepared platform was also evaluated implementing C26-tumor-bearing mice. Obtained data confirmed higher tumor accumulation and higher tumor residence time for targeted complex through MRI imaging due to the existence of SPION as a contrast agent in the core of the prepared complex. The prepared multimodal theranostic system provides a safe and effective platform for fighting against cancer.

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Nature 464:1067–1070. (PMID: 203056362855406)
Iezzi ME, Policastro L, Werbajh S, Podhajcer O, Canziani GA (2018) Front Immunol 9:273. (PMID: 295202745827546)
Kim BY, Rutka JT, Chan WC (2010) N Engl J Med 363:2434–2443. (PMID: 21158659)
Akbarzadeh M, Babaei M, Abnous K, Taghdisi SM, Peivandi MT, Ramezani M, Alibolandi M (2019) Int J Pharm 570:118645. (PMID: 31465835)
Oroojalian F, Babaei M, Taghdisi SM, Abnous K, Ramezani M, Alibolandi M (2018) J Controlled Release Off J Controlled Release Soc 288:45–61.
Alibolandi M, Hoseini F, Mohammadi M, Ramezani P, Einafshar E, Taghdisi SM, Ramezani M, Abnous K (2018) Int J Pharm 549:67–75. (PMID: 30048777)
Bagheri E, Ansari L, Abnous K, Taghdisi SM, Charbgoo F, Ramezani M, Alibolandi M (2018) J Controlled Release Off J Controlled Release Soc 277:57–76.
Alibolandi M, Abnous K, Mohammadi M, Hadizadeh F, Sadeghi F, Taghavi S, Jaafari MR, Ramezani M (2017) J Controlled Release Off J Controlled Release Soc 264:228–236.
Alibolandi M, Ramezani M, Abnous K, Sadeghi F, Hadizadeh F (2015) J Nanoparticle Res 17:76.
Lammers T, Hennink WE, Storm G (2008) Br J Cancer 99:392–397. (PMID: 186483712527811)
Babaei M, Abnous K, Taghdisi SM, Farzad SA, Peivandi MT, Ramezani M, Alibolandi M (2017) Nanomedicine 12:1261–1279. (PMID: 28520529)
Iyer AK, Khaled G, Fang J, Maeda H (2006) Drug Discovery Today 11:812–818. (PMID: 16935749)
Matsumura HMY (1986) Cancer Res 46:6387–6392. (PMID: 2946403)
Allen TM (2002) Nat Rev Cancer 2:750–763. (PMID: 12360278)
Freeland-Graves J, Proffitt MJ (2002) J Am Chem Soc 124:7636–7636.
Keeler BD, Brookes MJ (2013) Br J Pharmacol 168:1313–1315. (PMID: 232783843596638)
Torti SV, Torti FM (2013) Nat Rev Cancer 13:342–355. (PMID: 235948554036554)
Salehi S, Saljooghi A, Shiri A (2016) Eur J Pharmacol 781:209–217. (PMID: 27090924)
Cappellini MD, Taher A (2009) Acta Haematol 122:165–173. (PMID: 19907154)
Richardson DR, Baker E (1990) Biochim Biophys Acta (BBA) Mol Cell Res 1053:1–12.
Richardson D, Baker E (1991) Biochim Biophys Acta (BBA) Mol Cell Res 1093:20–28.
Kalinowski DS, Richardson DR (2005) Pharmacol Rev 57:547–583. (PMID: 16382108)
Stucky S, Koch N, Heinz U, Hegetschweiler K (2008) Chem Papers 62:388.
Freeman MW, Arrott A, Watson JHL (1960) J Appl Phys 31:S404–S405.
Amstad E, Zurcher S, Mashaghi A, Wong JY, Textor M, Reimhult E (2009) Small 5:1334–1342. (PMID: 19242944)
Gu XM, Jiang ZF, Huang HC (2010) Chin J Integr Med 16:276–282. (PMID: 20694785)
Veiseh O, Gunn JW, Zhang M (2010) Adv Drug Deliv Rev 62:284–304. (PMID: 19909778)
Tartaj P, Morales MP, González-Carreño T, Veintemillas-Verdaguer S, Serna CJ (2005) J Magn Magn Mater 290–291:28–34.
Neuberger T, Schöpf B, Hofmann H, Hofmann M, von Rechenberg B (2005) J Magn Magn Mater 293:483–496.
Jordan A, Scholz R, Maier-Hauff K, Johannsen M, Wust P, Nadobny J, Schirra H, Schmidt H, Deger S, Loening S, Lanksch W, Felix R (2001) J Magn Magn Mater 225:118–126.
Ito A, Shinkai M, Honda H, Kobayashi T (2005) J Biosci Bioeng 100:1–11. (PMID: 16233845)
Huber DL (2005) Small 1:482–501. (PMID: 17193474)
Gupta AK, Gupta M (2005) Biomaterials 26:3995–4021. (PMID: 15626447)
Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA (2006) Neurosci Lett 406:189–193. (PMID: 16919875)
Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, Zywicke H, Miller B, van Gelderen P, Moskowitz BM, Duncan ID, Frank JA (2001) Nat Biotechnol 19:1141–1147. (PMID: 11731783)
Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O’Regan RM (2006) Lancet Oncol 7:657–667. (PMID: 16887483)
Sengupta S, Sasisekharan R (2007) Br J Cancer 96:1315–1319. (PMID: 174063642360169)
Ruoslahti E, Bhatia SN, Sailor MJ (2010) J Cell Biol 188:759–768. (PMID: 202313812845077)
Bouchard PR, Hutabarat RM, Thompson KM (2010) Annu Rev Pharmacol Toxicol 50:237–257. (PMID: 20055704)
Proske D, Blank M, Buhmann R, Resch A (2005) Appl Microbiol Biotechnol 69:367–374. (PMID: 16283295)
Song S, Wang L, Li J, Fan C, Zhao J (2008) TrAC, Trends Anal Chem 27:108–117.
Evtugyn G, Porfireva A, Stepanova V, Sitdikov R, Stoikov I, Nikolelis D, Hianik T (2014) Electroanalysis 26:2100–2109.
Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R (2006) Proc Natl Acad Sci USA 103:6315–6320. (PMID: 16606824)
Ku TH, Zhang T, Luo H, Yen TM, Chen PW, Han Y, Lo YH (2015) Sensors 15:16281–16313. (PMID: 26153774)
Mayer G (2009) Angew Chem 48:2672–2689.
Nimjee SM, Rusconi CP, Sullenger BA (2005) Annu Rev Med 56:555–583. (PMID: 15660527)
Yin X, Russek SE, Zabow G, Sun F, Mohapatra J, Keenan KE, Boss MA, Zeng H, Liu JP, Viert A, Liou SH, Moreland J (2018) Sci Rep 8:11863. (PMID: 300898816082888)
Sennino B, Falcon BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM (2007) Can Res 67:7358–7367.
Vaught JD, Bock C, Carter J, Fitzwater T, Otis M, Schneider D, Rolando J, Waugh S, Wilcox SK, Eaton BE (2010) J Am Chem Soc 132:4141–4151. (PMID: 20201573)
Gramlich PM, Wirges CT, Manetto A, Carell T (2008) Angew Chem 47:8350–8358.
Javaherian S, Musheev MU, Kanoatov M, Berezovski MV, Krylov SN (2009) Nucleic Acids Res 37:e62. (PMID: 193047512677892)
Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W, Zhao L, Tang SC, Wu D, Korkaya H, Maihle NJ, Liu HY (2018) Mol Ther Nucleic acids 10:317–330. (PMID: 29499944)
McKeen H, Byrne C, Valentine A, O’Rourke M, Yakkundi A, McClelland K, McAlpine K, Hirst DG, Robson T (2008) Breast Cancer Res 10:P1. (PMID: 3300704)
Iliuk AB, Hu L, Tao WA (2011) Anal Chem 83:4440–4452. (PMID: 215241283115435)
Kim J, Kim D, Lee JB (2017) RSC Adv 7:1643–1645.
Girvan AC, Teng Y, Casson LK, Thomas SD, Juliger S, Ball MW, Klein JB, Pierce WM Jr, Barve SS, Bates PJ (2006) Mol Cancer Ther 5:1790–1799. (PMID: 16891465)
Dapic V, Abdomerovic V, Marrington R, Peberdy J, Rodger A, Trent JO, Bates PJ (2003) Nucleic Acids Res 31:2097–2107. (PMID: 12682360153744)
Dapic V, Bates PJ, Trent JO, Rodger A, Thomas SD, Miller DM (2002) Biochemistry 41:3676–3685. (PMID: 11888284)
Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM (1999) J Biol Chem 274:26369–26377. (PMID: 10473594)
Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, Trent JO, Miller DM, Bates PJ (2001) J Biol Chem 276:43221–43230. (PMID: 11555643)
Taghavi F, Gholizadeh M, Saljooghi AS, Ramezani M (2017) MedChemComm 8:1953–1964. (PMID: 301087166072274)
Ryabukhin YI, Faleeva LN, Korobkova VG (1983) Chem Heterocycl Compd 19:332–336.
Zhang L, Dong WF, Sun HB (2013) Nanoscale 5:7664–7684. (PMID: 23877222)
Johnson RK, Zink-Sharp A, Glasser WG (2011) Cellulose 18:1599–1609.
Snyder SL, Sobocinski PZ (1975) Anal Biochem 64:284–288. (PMID: 1137089)
Gyarmati B, Hegyesi N, Pukanszky B, Szilagyi A (2015) Express Polym Lett 9:154–164.
Cayot P, Tainturier G (1997) Anal Biochem 249:184–200. (PMID: 9212870)
Zhu N, Ji H, Yu P, Niu J, Farooq MU, Akram MW, Udego IO, Li H, Niu X (2018) Nanomaterials 8:810. (PMID: 6215286)
Wang C, Yan Q, Liu HB, Zhou XH, Xiao SJ (2011) Langmuir ACS J Surfaces Colloids 27:12058–12068.
Lui GY, Obeidy P, Ford SJ, Tselepis C, Sharp DM, Jansson PJ, Kalinowski DS, Kovacevic Z, Lovejoy DB, Richardson DR (2013) Mol Pharmacol 83:179–190. (PMID: 23074173)
Amano S, Kaino S, Shinoda S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I (2020) BMC Cancer 20:681. (PMID: 326987927374870)
Perrone R, Butovskaya E, Lago S, Garzino-Demo A, Pannecouque C, Palu G, Richter SN (2016) Int J Antimicrob Agents 47:311–316. (PMID: 270327484840014)
Morita Y, Leslie M, Kameyama H, Volk DE, Tanaka T (2018) Cancers 10:80. (PMID: 5876655)
Taghavi F, Saljooghi AS, Gholizadeh M, Ramezani M (2016) MedChemComm 7:2290–2298.
Ahangaran F, Hassanzadeh A, Nouri S (2013) Int Nano Lett 3:23.
Angulo-Molina A, Méndez-Rojas MÁ, Palacios-Hernández T, Contreras-López OE, Hirata-Flores GA, Flores-Alonso JC, Merino-Contreras S, Valenzuela O, Hernández J, Reyes-Leyva J (2014) J Nanopart Res 16:2528.
Mikhaylova M, Kim DK, Berry CC, Zagorodni A, Toprak M, Curtis ASG, Muhammed M (2004) Chem Mater 16:2344–2354.
Esmaeilpour M, Javidi J, Dodeji FN, Abarghoui MM (2014) J Mol Catal A Chem 393:18–29.
Peng N, Wu B, Wang L, He W, Ai Z, Zhang X, Wang Y, Fan L, Ye Q (2016) Biomater Sci 4:1802–1813. (PMID: 27792228)
Rao CNR, Venkataraghavan R, Kasturi TR (1964) Can J Chem 42:36–42.
Wileman T, Harding C, Stahl P (1985) Biochem J 232:1–14. (PMID: 28677591152830)
Martin-Sanchez D, Gallegos-Villalobos A, Fontecha-Barriuso M, Carrasco S, Sanchez-Nino MD, Lopez-Hernandez FJ, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB (2017) Sci Rep 7:41510. (PMID: 281397175282523)

Keywords: Aptamer; Cytotoxicity; Deferasirox; Drug delivery; SPION

0 (Antineoplastic Agents)
0 (Aptamers, Nucleotide)
0 (Contrast Media)
0 (Immobilized Nucleic Acids)
0 (Iron Chelating Agents)
0 (Magnetite Nanoparticles)
0 (Propylamines)
0 (Silanes)
13822-56-5 (3-aminopropyltrimethoxysilane)
V8G4MOF2V9 (Deferasirox)

Date Created: 20201106 Date Completed: 20210816 Latest Revision: 20240226

20240226

10.1007/s00775-020-01834-8

33156416